Jacob Van Naarden, who oversees Eli Lilly's oncology business and now leads its business development, highlighted the company's ambition to utilize its financial success, particularly from GLP-1 drugs like Mounjaro and Zepbound, to fund acquisitions.
In 2026 alone, Lilly plans to spend over $10 billion upfront on eight acquisitions, a significant increase from the $4 billion spent on approximately 40 deals in the previous year. This strategy reflects a shift from Lilly's historical focus on early-stage, lower-cost assets to pursuing more advanced and potentially lucrative experimental drugs.
The company's market capitalization has surged to around $1 trillion, making it the first healthcare company to reach this milestone, which positions it to compete more aggressively in the pharmaceutical sector. Lilly's recent acquisition of Centessa Pharmaceuticals, potentially valued at $7.8 billion, exemplifies this new direction.
Van Naarden emphasized that the company is open to exploring a wide range of opportunities beyond its traditional specialties, indicating a flexible and expansive approach to future deals